We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.
The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ...
Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.
Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.
Submit an eRX through your electronic medical record system
Specialty Pharmacy: PANTHERx Rare Pharmacy
NPI: 1316213531 or 1750843314
Address: 1120 Stevenson Mill Road, Suite 400 Coraopolis, PA 15108
Note: Submitting an eRX does not enroll your patient in the Navigator ProgramTM.
No refrigeration provides on-the-go potential.1
The starting total daily dosage of CUVRIOR in adults ranges from 300 mg to 3000 mg orally in divided doses taken just 2 times a day.1
Administer CUVRIOR1 on an empty stomach:
DPA should be discontinued before starting CUVRIOR. Use the table in the CUVRIOR Prescribing Information to find the recommended starting total daily dose of CUVRIOR when switching a patient from DPA.
If switching a patient from a trientine hydrochloride formulation to CUVRIOR, note that the content of the trientine base is not the same and is not substitutable on a milligram-per-milligram basis.
2HCI: 250 mg = 167 mg of trientine base
CUVRIOR: 300 mg = 150 mg of trientine base
Adjust the total daily dosage of CUVRIOR according to clinical assessment and serum non-ceruloplasmin copper (NCC) levels.
Evaluate serum NCC levels when initiating CUVRIOR treatment, after 3 months of treatment, and approximately every 6 months thereafter. Therapy may also be monitored periodically (every 6 to 12 months) with measurement of 24-hour urinary copper excretion (UCE).
See Important Safety Information below.
There is no standard conversion from zinc.
Adjust the total daily dosage of CUVRIOR according to clinical assessment and serum non-ceruloplasmin copper (NCC) levels. Evaluate serum NCC levels when initiating CUVRIOR treatment, after 3 months of treatment and approximately every 6 months thereafter. Therapy may also be monitored periodically (every 6 to 12 months) with measurement of 24-hour urinary copper excretion (UCE) (see Important Safety Information below).
If the number of CUVRIOR tablets prescribed per day cannot be equally divided among doses, then divide the total daily dosage such that the higher number of tablets is administered with the first daily dose. Table 2 provides the recommended approach to administration of CUVRIOR tablets to achieve the total daily dosage.
1. CUVRIOR [package insert]. Chicago, IL: Orphalan SA. 2. CUVRIOR-trientine tetrahydrochloride tablet, film coated. National Library of Medicine website. Accessed September 5, 2023. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f73feeae-62ad-401e-b9f7-5cb269127750 3. GALZIN-zinc acetate tablet capsule. National Library of Medicine website. Accessed September 5, 2023. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a0c72bff-20f3-4241-b966-34a95178d1a3 4. CUPRIMINE-penicillamine capsule. National Library of Medicine website. Accessed September 5, 2023. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=80e736d3-2017-4d68-94b4-38255c3c59c6 5. SYPRINE-trientine hydrochloride capsule. National Library of Medicine website. Accessed September 5, 2023. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c34f77a7-996b-4470-b5df-d946a7fe5dbe
CUVRIOR is a copper chelator indicated for the treatment of adult patients with stable Wilson disease who are de-coppered and tolerant to penicillamine.
The most common adverse reactions (>5%) are abdominal pain, change of bowel habits, rash, alopecia, and mood swings.
To report SUSPECTED ADVERSE REACTIONS, contact Orphalan at 1-800-961-8320 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Please see full Prescribing Information.